InMode Ltd Sees 6% Increase in Stock Prices After Announcing Q4 and Fiscal Year 2022 Revenue Estimates
January 12, 2023
Trending News ☀️
INMODE ($NASDAQ:INMD): InMode Ltd, a medical technologies company, is seeing a 6% increase in its stock prices pre-market after announcing its Q4 and fiscal year 2022 revenue estimates. The company has seen a steady increase in its stock prices over the past few months, and the latest announcement has further strengthened investor confidence in the company. The news of the expected revenue increase has been welcomed by investors and analysts alike, as they had been expecting the company to make a strong showing this year. InMode’s technology solutions are used in a variety of medical procedures, and its products are used by surgeons and medical professionals around the world. The company has seen an increase in demand for its products and services due to the growing demand for technologically advanced medical solutions.
InMode has also recently acquired a number of startups in the medical technology space, which has allowed them to expand their product offerings and increase their global presence. These acquisitions have allowed the company to strengthen its competitive edge in the industry, and have helped them become one of the leading players in the market. Overall, InMode is seeing a positive response from investors and analysts alike, as the company is expected to have a strong year ahead.
Share Price
On Wednesday, InMode Ltd, a medical technology company, announced its estimated revenue for the fourth quarter of 2022 and the full fiscal year. Following the announcement, the company’s stock rose 6%, opening at $37.4 and closing at $33.2. This was a slight increase from the previous closing price of 36.7. The news was welcomed by investors, as it was a sign of confidence from the company that their revenues would continue to grow into the next fiscal year. The company is currently in the midst of an aggressive expansion plan, with the aim of becoming a global leader in medical technology. As part of this plan, they have been investing heavily in research and development and expanding their product range.
The stock price has been relatively steady for the past few weeks, indicating that investors are confident in the company’s future prospects. Analysts believe that this stock price increase is a positive sign for the company, and that it is likely to remain strong in the coming months. InMode Ltd is well-positioned to take advantage of the increasing demand for medical technology products, and their estimated revenue figures suggest that they are on track to meet their growth targets for 2022. All in all, this news is a positive sign for the company and its investors. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Inmode Ltd. More…
| Total Revenues | Net Income | Net Margin |
| 431.24 | 176.5 | 40.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Inmode Ltd. More…
| Operations | Investing | Financing |
| 177.32 | -102.01 | -64.63 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Inmode Ltd. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 578.98 | 70.68 | 5.01 |
Key Ratios Snapshot
Some of the financial key ratios for Inmode Ltd are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 46.1% | 55.6% | 44.5% |
| FCF Margin | ROE | ROA |
| 40.8% | 28.9% | 20.7% |
VI Analysis
INMODE LTD has a medium risk rating according to the VI Risk Rating system, which takes into account the company’s fundamentals and long-term potential. This risk rating is based on an evaluation of financial and business aspects, providing an indication of potential risks. The VI App has also flagged one risk warning in the financial journal which suggests that further analysis is required. When making an investment, it is important to consider the amount of risk associated with it. VI Risk Rating enables investors to gain a better understanding of the risks associated with a particular company or industry. By using the app, investors can receive insight into both the financial and business aspects of a company, allowing them to make more informed decisions when investing. The VI App provides a comprehensive risk rating system that can be used to determine the level of risk associated with any investment. This system takes into account the company’s fundamentals, its long-term potential, as well as any warning signals detected in the financial journal. By taking the time to research and analyze potential investments, investors can make more informed decisions and reduce their risk exposure. More…
VI Peers
The market for aesthetic medical device is highly competitive with InMode Ltd. facing competition from Cutera Inc., Viveve Medical Inc., and Apyx Medical Corp. All four companies offer a range of products that target different areas of the body and address different aesthetic concerns. InMode Ltd. has a strong portfolio of products that are backed by clinical data and have a proven track record of safety and efficacy. The company’s products are also available in a variety of price points to meet the needs of different consumers.
– Cutera Inc ($NASDAQ:CUTR)
Cutera Inc is a medical device company that provides aesthetic treatments to patients worldwide. Founded in 1998, Cutera is headquartered in Brisbane, California, and has a market cap of 931.59M as of 2022. The company’s Return on Equity is -111.73%. Cutera’s products are used by physicians and other healthcare professionals to treat conditions such as wrinkles, acne, vascular lesions, and unwanted hair. The company’s products include laser and light-based devices, intense pulsed light devices, and radiofrequency devices.
– Viveve Medical Inc ($NASDAQ:VIVE)
Viveve Medical Inc. is a medical technology company that focuses on the treatment of female intimate health conditions. The company’s flagship product is the Viveve System, which is used to treat vaginal laxity, the condition where the vaginal walls become stretched and loose. The Viveve System uses radiofrequency energy to heat tissue and stimulate collagen production, which results in tighter, healthier tissue.
Viveve Medical Inc has a market cap of 6.19M as of 2022. The company’s Return on Equity is -179.17%. The company’s flagship product is the Viveve System, which is used to treat vaginal laxity. The Viveve System uses radiofrequency energy to heat tissue and stimulate collagen production, which results in tighter, healthier tissue.
– Apyx Medical Corp ($NASDAQ:APYX)
Apyx Medical Corp is a medical device company that develops, manufactures, and markets radiofrequency (RF) products for the global surgical market. The company’s products include the Renuvion System, a minimally invasive RF technology for tissue remodeling and tightening, and the J-Plasma System, a next-generation plasma-based technology.
Apyx Medical Corp has a market cap of 149.01M as of 2022, a Return on Equity of -22.62%. The company develops, manufactures, and markets radiofrequency (RF) products for the global surgical market. The company’s products include the Renuvion System, a minimally invasive RF technology for tissue remodeling and tightening, and the J-Plasma System, a next-generation plasma-based technology.
Summary
INMODE LTD is a publicly traded company that recently announced their Q4 and Fiscal Year 2022 revenue estimates. This positive movement in their stock prices may be an indication of investor confidence in their future prospects. Analysts are recommending investors to look into INMODE LTD as a profitable and reliable long-term investment.
In addition, research has indicated that the company’s performance has been relatively consistent over the past few years, making it a reliable investment. As with any investment, investors should do their own research to make sure INMODE LTD is the right choice for them.
Related Posts
Recent Posts
